Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?

Damoiseaux, Jan

doi:10.1136/annrheumdis-2014-205193

Cited by 6 publications

(5 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, clinicians should take into account that testing algorithms are often defined for the whole spectrum of SARD. If testing for ARA is broadly included in these algorithms, this will increase the ratio of false- and true-positive results [ 28 ].…”

Section: Influence Of Testing Algorithms In Routine Clinical Practicementioning

confidence: 99%

Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

Damoiseaux

Smeets

Bonroy

2022

Journal of Translational Autoimmunity

Self Cite

View full text Add to dashboard Cite

The ACR/EULAR classification criteria for systemic sclerosis (SSc) entail three autoantibodies: anti-centromere antibodies (ACA), anti-topoisomerase I antibodies (ATA), and anti-RNA-polymerase III antibodies (ARA). The importance of ACA and ATA in the classification criteria is evidence based, but the diagnostic value is overestimated by clinicians. Fortunately, these autoantibodies are characterized by good agreement between different immuno-assays. Inclusion of ARA, however, is based on limited evidence and is related to limited agreement between different immuno-assays. Harmonization of immuno-assays in terms of interpretation based on likelihood ratio's may improve future classification criteria for SSc and this needs to be achieved by close collaboration between clinicians, laboratory specialists and the diagnostic industry.

show abstract

Section: Influence Of Testing Algorithms In Routine Clinical Practicementioning

confidence: 99%

Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

Damoiseaux

Smeets

Bonroy

2022

Journal of Translational Autoimmunity

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some doubts have been raised on the opportunity to routinely test anti-RNAP3 in the context of the suspect of systemic autoimmune diseases. 19 On the other hand, ACR and EULAR experts strongly support the notion that anti-RNAP3 can be helpful in the diagnosis and classification of SSc when a specific clinical suspect is present. 18 An example of clinical setting inducing the suspect of SSc may be represented by patients with VEDOSS red flags (Raynaud’s phenomenon and puffy fingers, or ANA positivity), 20 but other scenarios are also possible.…”

Section: Introductionmentioning

confidence: 99%

Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen

Lazzaroni

Airò

2018

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

Anti-RNA Polymerase III antibodies are the most frequent anti-nuclear antibodies in systemic sclerosis, after anticentromere and anti-Topoisomerase I. Considering their specificity for systemic sclerosis, they have been included in 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis. They were first identified in 1993 using an immunoprecipitation method; the subsequent diffusion of commercial assays, based on the enzyme-linked immunosorbent assay or multiplex line immunoblot techniques, has allowed an increasing number of systemic sclerosis patients to be tested for this autoantibody; nevertheless, the diffusion of this test in systemic sclerosis patients is probably still sub-optimal. Anti-RNA Polymerase III antibodies have been associated with important clinical manifestations: rapid and diffuse cutaneous involvement, joint contractures, scleroderma renal crisis, gastric antral vascular ectasia and malignancies synchronous to systemic sclerosis onset. Moreover, other possible clinical associations, including pulmonary hypertension, still need confirmation. Since the correct approach for screening for anti-RNA Polymerase III antibodies in patients with suspected or definite systemic sclerosis is still debated, possible strategies are proposed here. Moreover, issues that are still controversial are discussed, including the interpretation of multiple simultaneous positivity for anti-RNA Polymerase III antibodies and other autoantibodies in line immunoassay, and the possible relevance of anti-RNA Polymerase III antibodies titre.

show abstract

“…31 Besides autoantibodies to CENP-B and topoisomerase I (Scl-70), autoantibodies to RNA polymerase III have also been included. Although the arguments for this addition can be disputed, 32 the criteria require inclusion of these autoantibodies in the testing algorithm. Since most multiparametric assays for SARD do not yet include RNA polymerase III, different strategies for monospecific detection of autoantibodies to RNA polymerase III can be envisaged.…”

Section: Multiparametric Autoantibody Diagnostics In Systemic Autoimmmentioning

confidence: 99%

Multiparametric autoimmune diagnostics: recent advances

Damoiseaux¹

2016

PLMI

Self Cite

View full text Add to dashboard Cite

Autoimmune diagnostics in a routine clinical laboratory is constantly challenged by the discovery of new autoantibodies and technical innovations in the immunoassays applied. These challenges are, in particular, combined in the multiparametric immunoassays. Appropriate positioning of multiparametric immunoassays within the laboratory requires integrated knowledge of the clinical performance of the test system for each individual antigen, the conditions prescribed in disease criteria and/or guidelines, and the demands of the clinicians. This review provides a summary of the multiparametric immunoassays available, as well as the applications and restrictions in routine clinical practice.

show abstract

Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?

Cited by 6 publications

References 6 publications

Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen

Multiparametric autoimmune diagnostics: recent advances

Contact Info

Product

Resources

About